NCT06957912 Transcutaneous Auricular Vagus Nerve Stimulation and Quality of Recovery After Major Noncardiac Surgery
| NCT ID | NCT06957912 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Vagus Nerve Stimulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 320 participants |
| Start Date | 2025-05-13 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 320 participants in total. It began in 2025-05-13 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel non-invasive neuromodulation technique. Existing evidence suggested that taVNS improves pain management, sleep quality, inflammatory responses, and gastrointestinal recovery after surgery. This study is designed to test the hypothesis that perioperative use of taVNS may improve quality of recovery in patients after major noncardiac surgery.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years but \<85 years. 2. Scheduled for elective or limited-time noncardiac surgery with expected duration ≥2 hours. Exclusion Criteria: 1. Lesions or infections of the auricle skin. 2. Recent or long-term use of cholinergic or anticholinergic medications. 3. Neurosurgery. 4. Expected mechanical ventilation with intubation for ≥1 day after surgery. 5. Diagnosed schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery. 6. Preoperative left ventricular ejection fraction (LVEF) \<30%, or those with sick sinus syndrome, sinus bradycardia (heart rate \<50 beats per minute), atrioventricular block of grade II or above, or implanted pacemaker. 7. Inability to communicate due to coma, severe dementia, or language barrier before surgery, or unable to cooperate with intervention. 8. American Society of Anesthesiologists physical status grade \>IV, or estimated survival \<24 hours.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT06957912 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Vagus Nerve Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06957912 currently recruiting?
Yes, NCT06957912 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT06957912 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06957912 clinical trial?
NCT06957912 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 320 participants.